Aveanna Healthcare (NASDAQ:AVAH) Price Target Raised to $11.00 at Barclays

Aveanna Healthcare (NASDAQ:AVAH) had its price objective boosted by research analysts at Barclays from $9.00 to $11.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective points to a potential upside of 13.55% from the stock’s current price.

A number of other equities analysts have also weighed in on AVAH. Truist Financial upped their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a research note on Friday, November 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Monday, December 29th. JPMorgan Chase & Co. upgraded Aveanna Healthcare from an “underweight” rating to a “neutral” rating and upped their price objective for the stock from $6.00 to $10.00 in a report on Thursday, September 18th. Zacks Research cut Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, October 20th. Finally, Jefferies Financial Group lifted their price target on shares of Aveanna Healthcare from $11.00 to $12.50 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Five analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Aveanna Healthcare has an average rating of “Hold” and a consensus target price of $11.06.

Aveanna Healthcare Stock Down 0.7%

NASDAQ:AVAH traded down $0.07 on Friday, hitting $9.69. The stock had a trading volume of 268,089 shares, compared to its average volume of 1,387,896. Aveanna Healthcare has a 1 year low of $3.67 and a 1 year high of $10.32. The firm’s fifty day simple moving average is $8.82 and its two-hundred day simple moving average is $7.73. The stock has a market cap of $2.02 billion, a P/E ratio of 26.94 and a beta of 2.06. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23.

Aveanna Healthcare (NASDAQ:AVAH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.08. The business had revenue of $621.94 million during the quarter, compared to the consensus estimate of $578.57 million. Aveanna Healthcare had a net margin of 3.29% and a negative return on equity of 143.55%. Analysts predict that Aveanna Healthcare will post -0.06 earnings per share for the current year.

Insiders Place Their Bets

In other Aveanna Healthcare news, insider Patrick A. Cunningham sold 12,445 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $7.85, for a total transaction of $97,693.25. Following the completion of the transaction, the insider owned 293,354 shares of the company’s stock, valued at $2,302,828.90. This represents a 4.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Edwin C. Reisz sold 17,613 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $7.85, for a total value of $138,262.05. Following the transaction, the insider directly owned 1,321,114 shares in the company, valued at $10,370,744.90. This trade represents a 1.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 32,857,606 shares of company stock worth $295,491,307. 7.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aveanna Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVAH. Allspring Global Investments Holdings LLC bought a new stake in Aveanna Healthcare during the 4th quarter valued at about $484,000. SG Americas Securities LLC grew its holdings in shares of Aveanna Healthcare by 15.2% during the fourth quarter. SG Americas Securities LLC now owns 19,906 shares of the company’s stock valued at $163,000 after buying an additional 2,624 shares during the last quarter. Diversified Trust Co. increased its position in shares of Aveanna Healthcare by 78.2% during the fourth quarter. Diversified Trust Co. now owns 19,400 shares of the company’s stock valued at $158,000 after acquiring an additional 8,516 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Aveanna Healthcare by 32.4% during the third quarter. JPMorgan Chase & Co. now owns 209,491 shares of the company’s stock valued at $1,858,000 after acquiring an additional 51,226 shares in the last quarter. Finally, Caxton Associates LLP purchased a new position in Aveanna Healthcare in the 3rd quarter worth approximately $488,000. 87.96% of the stock is owned by hedge funds and other institutional investors.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.